Maintenance Treatment of Anemia in Pre-dialysis Subjects With Chronic Kidney Disease on Darbepoetin Treatment Versus BAY85-3934

Inclusion Criteria: * Male or female subjects ≥ 18 years of age with anemia of chronic kidney disease (CKD) at screening * Estimated glomerular filtration rate (eGFR) of \< 60 mL/min/1.73 m2 (Modification of Diet in Renal Disease or the formula according to Matsuo, et al.) * Not on dialysis and not expected to begin dialysis during the treatment period of the study (at least 16 weeks from randomization) * Treated with darbepoetin via intravenous (IV) or subcutaneous (SC) route with a weekly, bi-weekly, or monthly dose, having had no more than one dose change within 8 weeks prior to randomization * At least one kidney * Mean screening hemoglobin (Hb) concentration of 10.0 to 12.0 g/dL * Men who agree to use adequate contraception when sexually active or women without childbearing potential Exclusion Criteria: * Subjects with significant acute or chronic bleeding, such as overt gastrointestinal bleeding * Active hemolysis or diagnosis of hemolytic syndrome * History of myelodysplastic syndrome, multiple myeloma, marrow fibrosis, or pure red-cell aplasia (PRCA) * History of hemosiderosis or hemochromatosis * Hereditary hemoglobinopathies (such as sickle cell disease and thalassemia major) * Aplastic anemia * Chronic lymphoproliferative diseases * Proliferative choroidal or retinal disease, such as neovascular age-related macular degeneration or proliferative diabetic retinopathy that is likely to require invasive treatment (intraocular injections or laser photocoagulation) during the study * Chronic inflammatory disease that could impact erythropoiesis (e.g., systemic lupus erythematosis, rheumatoid arthritis, celiac disease) even if it is currently in remission * Known hypersensitivity to the study drugs (active substances or excipients of the preparations) * Uncontrolled and symptomatic hyperparathyroidism * Uncontrolled active infection * Previous or concurrent cancer except cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta, Tis, and T1) or any cancer curatively treated \> 3 years prior to randomization * Any allograft (including renal allograft) in place and on immunosuppressive therapy or a scheduled kidney transplant within the next 16 weeks (being on a waiting list does not exclude the subject)